SinoMab BioScience Limited
HKEX:3681.HK
1.13 (HKD) • At close November 14, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
2024 Q2 | 2023 Q4 | 2023 Q2 | 2022 Q4 | 2022 Q2 | 2021 Q4 | 2021 Q2 | 2020 Q4 | 2020 Q2 | 2019 Q4 | 2019 Q2 | 2019 Q1 | 2018 Q4 | 2018 Q2 | 2018 Q1 | 2017 Q4 | 2017 Q2 | 2017 Q1 | 2016 Q4 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 6.081 | -4.077 | 8.469 | -3.425 | 7.457 | 26.657 | 0 | 12.76 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cost of Revenue
| 1.483 | 0 | 0.943 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Gross Profit
| 4.598 | -4.077 | 7.526 | -3.425 | 7.457 | 26.657 | 0 | 12.76 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Gross Profit Ratio
| 0.756 | 1 | 0.889 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Reseach & Development Expenses
| 55.035 | 68.659 | 66.75 | 98.237 | 82.131 | 109.131 | 89.982 | 55.586 | 47.816 | 181.562 | 32.78 | 53.586 | 53.586 | 11.821 | 11.821 | 11.821 | 8.151 | 8.151 | 8.151 |
General & Administrative Expenses
| 34.205 | 47.241 | 50.2 | 48.578 | 33.849 | 99.074 | 32.861 | 21.055 | 50.03 | 49.27 | 12.019 | 15.386 | 15.386 | 0.504 | 0.504 | 0.504 | 0.248 | 0.248 | 0.248 |
Selling & Marketing Expenses
| 0 | 0.174 | 0 | 0.164 | 0 | 1.465 | 0 | 0.925 | 0 | 0.255 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SG&A
| 34.205 | 47.415 | 50.2 | 48.742 | 33.849 | 100.539 | 32.861 | 21.98 | 50.03 | 49.525 | 12.019 | 15.386 | 15.386 | 0.504 | 0.504 | 0.504 | 0.248 | 0.248 | 0.248 |
Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -137.943 | -137.943 | -137.943 | -26.024 | -26.024 | -26.024 | -18.297 | -18.297 | -18.297 |
Operating Expenses
| 89.24 | 116.074 | 138.42 | 143.703 | 149.107 | 213.857 | 111.904 | 70.974 | 79.316 | 231.896 | 45.041 | -68.972 | -68.972 | -13.7 | -13.7 | -13.7 | -9.899 | -9.899 | -9.899 |
Operating Income
| -84.642 | -120.151 | -109.424 | -150.404 | -108.523 | -183.013 | -122.843 | -64.806 | -97.846 | -231.087 | -44.799 | -68.972 | -68.972 | -13.7 | -13.7 | -13.7 | -9.899 | -9.899 | -9.899 |
Operating Income Ratio
| -13.919 | 29.47 | -12.921 | 43.914 | -14.553 | -6.865 | 0 | -5.079 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Other Income Expenses Net
| -5.98 | 11.136 | -24.672 | 10.036 | -35.267 | 9.222 | 8.44 | 23.046 | 17.006 | 1.151 | -1.547 | -0.099 | -0.099 | -7.203 | -7.203 | -7.203 | -3.077 | -3.077 | -3.077 |
Income Before Tax
| -90.622 | -109.015 | -134.096 | -140.368 | -143.79 | -173.791 | -114.403 | -41.76 | -80.84 | -229.936 | -46.346 | -69.071 | -69.071 | -20.903 | -20.903 | -20.903 | -12.975 | -12.975 | -12.975 |
Income Before Tax Ratio
| -14.902 | 26.739 | -15.834 | 40.983 | -19.283 | -6.52 | 0 | -3.273 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Income Tax Expense
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.486 | 0.486 | 0.486 | -6.445 | -6.445 | -6.445 | -2.336 | -2.336 | -2.336 |
Net Income
| -90.622 | -109.015 | -134.096 | -140.368 | -143.79 | -173.791 | -114.403 | -41.76 | -80.84 | -229.936 | -46.346 | -69.071 | -69.071 | -20.903 | -20.903 | -20.903 | -11.994 | -11.994 | -11.994 |
Net Income Ratio
| -14.902 | 26.739 | -15.834 | 40.983 | -19.283 | -6.52 | 0 | -3.273 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS
| -0.085 | -0.11 | -0.13 | -0.14 | -0.15 | -0.18 | -0.11 | -0.042 | -0.08 | -0.26 | -0.058 | -0.083 | -0.083 | -0.021 | -0.021 | -0.021 | -0.012 | -0.012 | -0.012 |
EPS Diluted
| -0.085 | -0.11 | -0.13 | -0.14 | -0.15 | -0.18 | -0.11 | -0.042 | -0.08 | -0.26 | -0.058 | -0.083 | -0.083 | -0.021 | -0.021 | -0.021 | -0.012 | -0.012 | -0.012 |
EBITDA
| -75.075 | -108.334 | -102.107 | -140.484 | -103.81 | -175.607 | -120.822 | -62.376 | -96.234 | -229.76 | -43.89 | -66.364 | -66.364 | -18.81 | -18.81 | -18.81 | -10.024 | -10.024 | -10.024 |
EBITDA Ratio
| -12.346 | 26.572 | -12.057 | 41.017 | -13.921 | -6.588 | 0 | -4.888 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |